Biopharma Dealmaking Quarterly Statistics, Q4 2013
A look at financing, M&A, and alliance activity October–December 2013
Biopharma financing totaled $6.4 billion, a 39% increase over Q3. Twenty-three M&As were completed with a combined potential value of $19.8 billion, and there were 103 biopharma alliances totaling $2.5 billion in potential pre-commercialization value, down 25% from the previous quarter.
You may also be interested in...
AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.
The richly funded start-up is an unlikely collaboration between rival oncology research centers, both with immunotherapy programs that require complicated cell therapy processes. Coming together under one roof doesn’t mean the competition has ended.
Shire is buying ViroPharma at a steep premium to acquire its pipeline assets, notably C1 esterase inhibitor Cinryze, which the London-listed specialty pharma plans to expand internationally, initially to treat hereditary angioedema and later for other rare diseases.